PL3558339T3 - Multimeryczne polipeptydy modulujące limfocyty t i sposoby ich stosowania - Google Patents

Multimeryczne polipeptydy modulujące limfocyty t i sposoby ich stosowania

Info

Publication number
PL3558339T3
PL3558339T3 PL17884258.9T PL17884258T PL3558339T3 PL 3558339 T3 PL3558339 T3 PL 3558339T3 PL 17884258 T PL17884258 T PL 17884258T PL 3558339 T3 PL3558339 T3 PL 3558339T3
Authority
PL
Poland
Prior art keywords
multimeralic
methods
cell modulating
modulating polypeptides
polypeptides
Prior art date
Application number
PL17884258.9T
Other languages
English (en)
Inventor
Iii Ronald D. Seidel
Rodolfo CHAPARRO
Original Assignee
Cue Biopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cue Biopharma, Inc. filed Critical Cue Biopharma, Inc.
Publication of PL3558339T3 publication Critical patent/PL3558339T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
PL17884258.9T 2016-12-22 2017-12-20 Multimeryczne polipeptydy modulujące limfocyty t i sposoby ich stosowania PL3558339T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662438272P 2016-12-22 2016-12-22
US201762470774P 2017-03-13 2017-03-13
US201762555435P 2017-09-07 2017-09-07
US201762582132P 2017-11-06 2017-11-06
PCT/US2017/067663 WO2018119114A1 (en) 2016-12-22 2017-12-20 T-cell modulatory multimeric polypeptides and methods of use thereof

Publications (1)

Publication Number Publication Date
PL3558339T3 true PL3558339T3 (pl) 2024-08-05

Family

ID=62627190

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17884258.9T PL3558339T3 (pl) 2016-12-22 2017-12-20 Multimeryczne polipeptydy modulujące limfocyty t i sposoby ich stosowania

Country Status (19)

Country Link
US (21) US20190352363A1 (pl)
EP (2) EP3558339B1 (pl)
JP (4) JP7250677B2 (pl)
KR (1) KR102760578B1 (pl)
CN (6) CN110325205B (pl)
AU (1) AU2017379900B2 (pl)
BR (1) BR112019012964A2 (pl)
CA (1) CA3043630A1 (pl)
DK (1) DK3558339T5 (pl)
ES (1) ES2973548T3 (pl)
IL (4) IL297617B2 (pl)
MX (2) MX2019007611A (pl)
MY (1) MY202029A (pl)
PH (1) PH12019501413A1 (pl)
PL (1) PL3558339T3 (pl)
PT (1) PT3558339T (pl)
SI (1) SI3558339T1 (pl)
TW (2) TWI869327B (pl)
WO (1) WO2018119114A1 (pl)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018073606A2 (pt) 2016-05-18 2019-02-26 Cue Biopharma, Inc. polipeptídeos multiméricos moduladores de células t e métodos de uso dos mesmos
CN110325205B (zh) 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
WO2018129474A1 (en) 2017-01-09 2018-07-12 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CN111010875B (zh) * 2017-03-15 2024-04-05 库尔生物制药有限公司 用于调节免疫应答的方法
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
SG11201909949XA (en) 2017-05-24 2019-11-28 Pandion Therapeutics Inc Targeted immunotolerance
CN111315768A (zh) 2017-09-07 2020-06-19 库尔生物制药有限公司 具有缀合位点的t细胞调节性多聚体多肽及其使用方法
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
IL275426B2 (en) 2017-12-19 2025-03-01 Xencor Inc Engineered il-2 fc fusion proteins
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
EP3897746A4 (en) * 2018-12-19 2022-10-26 Cue Biopharma, Inc. MULTIMERIC T LYMPHOCYTE MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF
TWI856047B (zh) * 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
JP2022522405A (ja) * 2019-03-06 2022-04-19 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
US11739146B2 (en) 2019-05-20 2023-08-29 Pandion Operations, Inc. MAdCAM targeted immunotolerance
WO2020243315A1 (en) * 2019-05-29 2020-12-03 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
EP3986448A4 (en) * 2019-06-19 2023-07-12 Cue Biopharma, Inc. MULTIMERIC T-CELL-MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF
AU2020323893A1 (en) 2019-07-26 2022-02-17 Visterra, Inc. Interleukin-2 agents and uses thereof
EP4030897A4 (en) * 2019-09-20 2023-10-18 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
EP4048689A4 (en) * 2019-10-23 2023-11-01 Cue Biopharma, Inc. T-CELL MODULATING CHIMERIC MOLECULES AND METHOD OF USE THEREOF
CN114423497A (zh) * 2019-10-23 2022-04-29 库尔生物制药有限公司 修饰的细胞毒性t细胞及其使用方法
TW202128961A (zh) 2019-11-20 2021-08-01 美商安維塔生物科學股份有限公司 細胞激素融合蛋白及其醫藥組合物及治療應用
KR20220116513A (ko) 2019-12-20 2022-08-23 리제너론 파아마슈티컬스, 인크. 신규 il2 작용제 및 이의 사용 방법
AU2021206449A1 (en) 2020-01-10 2022-07-21 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
EP4090674A4 (en) * 2020-01-14 2024-01-24 Synthekine, Inc. Biased il2 muteins methods and compositions
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
WO2021195108A1 (en) * 2020-03-24 2021-09-30 Cue Biopharma, Inc. T cell modulatory polypeptides and methods of use thereof
WO2021222150A2 (en) 2020-04-28 2021-11-04 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
EP4149534A4 (en) 2020-05-12 2024-09-04 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING T CELLS AND METHODS OF USE THEREOF
AU2021299552A1 (en) * 2020-07-02 2023-02-02 Inhibrx Biosciences, Inc. Polypeptides comprising modified IL-2 polypeptides and uses thereof
CN113912735B (zh) * 2020-07-08 2025-03-28 南京师范大学 多肽二聚体及其用途
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
WO2022087458A1 (en) 2020-10-23 2022-04-28 Asher Biotherapeutics, Inc. Fusions with cd8 antigen binding molecules for modulating immune cell function
TW202237171A (zh) 2020-12-04 2022-10-01 美商威特拉公司 使用介白素-2藥劑之方法
EP4308142A4 (en) * 2021-03-19 2025-04-16 Cue Biopharma, Inc. T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF
AU2022238389A1 (en) * 2021-03-19 2023-10-05 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
EP4340866A4 (en) 2021-05-19 2025-05-21 Asher Biotherapeutics, Inc. Il-21 polypeptides and targeted constructs
KR20240019797A (ko) * 2021-06-09 2024-02-14 상하이 에피맙 바이오테라퓨틱스 컴퍼니, 리미티드 Ox40 및/또는 pd-l1에 결합하는 항체 및 이중특이적 결합 단백질
EP4366781A1 (en) 2021-07-09 2024-05-15 Bright Peak Therapeutics AG Checkpoint inhibitors conjugated to il-2, and uses thereof
KR20240041378A (ko) 2021-07-09 2024-03-29 브라이트 피크 테라퓨틱스 아게 체크포인트 억제제와 il-2의 접합체 및 이의 용도
WO2023281482A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Cd20-targeted il-2 and its uses
US20230201364A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Antibody conjugates and manufacture thereof
WO2023046156A1 (en) * 2021-09-26 2023-03-30 Wuxi Biologics (Shanghai) Co. Ltd. Il-2 variants and fusion proteins thereof
WO2023161857A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Bifunctional cytokine compositions
WO2023202035A1 (zh) * 2022-04-20 2023-10-26 北京大学宁波海洋药物研究院 受体偏向的peg化il-2变体组合及其应用
CN117186199A (zh) * 2022-05-31 2023-12-08 厦门大学 β2-微球蛋白封闭肽、其药物组合物及用途
PE20250753A1 (es) 2022-06-16 2025-03-13 Cephalon Llc Inmunoconjugados de il-2 atenuada-anticuerpo anti-pd-1 y usos de los mismos
US20240417436A1 (en) 2023-01-11 2024-12-19 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
WO2024150175A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated proteins and methods of use
WO2025059162A1 (en) * 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells

Family Cites Families (206)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
DK0648271T3 (da) 1991-08-20 2003-07-21 Us Gov Health & Human Serv Adenovirusmedieret overførsel af gener til mave-/tarmkanal
US6322789B1 (en) 1991-08-26 2001-11-27 Epimmune, Inc. HLA-restricted hepatitis B virus CTL epitopes
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
AU675204B2 (en) 1992-06-25 1997-01-30 City Of Hope Induction of cytolytic T-lymphocytes with cytomegalovirus polypeptides
CA2145641C (en) 1992-12-03 2008-05-27 Richard J. Gregory Pseudo-adenovirus vectors
GB9307371D0 (en) 1993-04-08 1993-06-02 Walls Alan J Fusion proteins
CA2166118C (en) 1993-06-24 2007-04-17 Frank L. Graham Adenovirus vectors for gene therapy
ES2256842T4 (es) 1993-10-25 2007-02-01 Canji, Inc. Vector de adenovirus recombinante y metodos de uso.
DE69519101T3 (de) 1994-07-29 2010-08-05 Sunol Molecular Corp., Miramar Mhc-komplexe und ihre verwendung
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
US5869270A (en) 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
US6211342B1 (en) 1996-07-18 2001-04-03 Children's Hospital Medical Center Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
US20050003431A1 (en) 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
US6218363B1 (en) 1996-08-28 2001-04-17 Thomas Jefferson University MHC peptides and methods of use
US6261801B1 (en) 1997-01-14 2001-07-17 Human Genome Sceineces, Inc. Nucleic acids encoding tumor necrosis factor receptor 5
KR100460583B1 (ko) 1997-02-13 2004-12-08 더 리전츠 오브 더 유니버시티 오브 캘리포니아 간세포 암의 예방 및 치료 방법
US7098306B2 (en) 1997-02-13 2006-08-29 The Regents Of The University Of California Method and compositions for treating hepatocellular cancer
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
AU727863B2 (en) 1997-05-08 2001-01-04 Oncothyreon Inc. Method for generating activated T-cells and antigen-pulsed antigen-presenting cells
US20030007978A1 (en) 1997-09-16 2003-01-09 Burrows Gregory G. Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
US6696304B1 (en) 1999-02-24 2004-02-24 Luminex Corporation Particulate solid phase immobilized protein quantitation
US6960652B2 (en) 1999-03-30 2005-11-01 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinaceous compounds
AU779395B2 (en) 1999-04-30 2005-01-20 Institut De Recherche Cliniques De Montreal (Ircm) Mutant human CD80 and compositions for and methods of making and using the same
US20020006664A1 (en) 1999-09-17 2002-01-17 Sabatini David M. Arrayed transfection method and uses related thereto
RU2002121771A (ru) * 2000-01-14 2004-03-10 Корикса Корпорейшн (Us) Композиции и способы для терапии и диагностики рака предстательной железы
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
CN1469926A (zh) * 2000-03-29 2004-01-21 科里克萨有限公司 治疗和诊断肺癌的组合物和方法
CA2410642A1 (en) 2000-05-25 2001-11-29 Sunol Molecular Corporation Modulation of t-cell receptor interactions
WO2004029197A2 (en) 2001-06-22 2004-04-08 Maxygen, Inc. Co-stimulatory molecules
US20020122820A1 (en) 2001-01-16 2002-09-05 Hildebrand William H. Soluble MHC artificial antigen presenting cells
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US6800748B2 (en) 2001-01-25 2004-10-05 Large Scale Biology Corporation Cytoplasmic inhibition of gene expression and expression of a foreign protein in a monocot plant by a plant viral vector
CA2440773A1 (en) 2001-03-14 2002-09-19 Dakocytomation Denmark A/S Novel mhc molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of mhc molecules
US6811785B2 (en) 2001-05-07 2004-11-02 Mount Sinai School Of Medicine Of New York University Multivalent MHC class II—peptide chimeras
WO2002093129A2 (en) 2001-05-15 2002-11-21 University Of Medicine & Dentistry Of New Jersey Methods for analyzing interactions between proteins in live and intact cells
WO2002099089A1 (en) 2001-06-04 2002-12-12 Corixa Corporation Compositions and methods for high-level, large-scale production of recombinant proteins
US20030017134A1 (en) 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
AU2002322211A1 (en) 2001-07-12 2003-01-29 Canvac Methods and compisitions for activation human t cells in vitro
EP1478740A2 (en) 2001-07-27 2004-11-24 Human Genome Sciences, Inc. Heteromultimeric tnf ligand family members
AU2002366433A1 (en) 2001-08-16 2003-09-09 Human Genome Sciences, Inc. Methods and compositions for treating metabolic bone diseases relating to human endokine alpha
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
AU2002357784B2 (en) * 2001-12-04 2008-07-31 Merck Patent Gmbh Immunocytokines with modulated selectivity
US6911321B2 (en) 2001-12-19 2005-06-28 Genentech, Inc. Non-human primate Fc receptors and methods of use
CN101143221A (zh) 2002-03-15 2008-03-19 布赖汉姆妇女医院 适合治疗剂全身性递送的中央气道给药
US8895020B2 (en) 2002-04-19 2014-11-25 Washington University Single chain trimers and uses therefor
CA2498319A1 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US7432351B1 (en) 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
WO2004076488A1 (en) 2003-02-27 2004-09-10 Theravision Gmbh A molecule which binds cd80 and cd86
AU2003901876A0 (en) 2003-04-17 2003-05-08 The Macfarlane Burnet Institute For Medical Research And Public Health Viral vector
US20050042641A1 (en) 2003-05-27 2005-02-24 Cold Spring Harbor Laboratory In vivo high throughput selection of RNAi probes
US7696306B2 (en) 2003-07-11 2010-04-13 Board of Agents of the University of Nebraska Compositions and methods for preventing or treating cancer
EP2216342B1 (en) 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
WO2005044982A2 (en) 2003-09-05 2005-05-19 Oregon Health & Science University Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
US7470513B2 (en) 2003-11-10 2008-12-30 Academia Sinica Risk assessment for adverse drug reactions
WO2005091956A2 (en) 2004-03-05 2005-10-06 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
EP1773383B1 (en) 2004-05-27 2012-09-12 Jon A. Weidanz Antibodies as t cell receptor mimics, methods of production and uses thereof
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
JP2008526205A (ja) 2004-12-31 2008-07-24 ジェネンテック・インコーポレーテッド Ｂｒ３に結合するポリペプチド及びその使用
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1996220B2 (en) 2006-03-06 2023-08-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
CA2523032A1 (en) * 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
KR20080082628A (ko) 2005-11-10 2008-09-11 리셉터 바이오로직스 인크 수용체 및 리간드 이소형태의 제조 방법
US7943133B2 (en) 2006-02-02 2011-05-17 Boston Biocom Llc Mesothelin antibody protein fusions and methods of use
US8518697B2 (en) 2006-04-04 2013-08-27 Washington University Single chain trimers and uses therefor
ZA200810677B (en) 2006-05-19 2010-03-31 Teva Pharma Fusion proteins, uses thereof and processes for producing same
EP1889851A1 (en) 2006-08-18 2008-02-20 Charite Universitätsmedizin-Berlin PAX2 and PAX8 as targets for immunologic and molecular tumour treatment strategies
US8992937B2 (en) 2006-08-28 2015-03-31 Washington University Disulfide trap MHC class I molecules and uses therefor
CA2886619A1 (en) 2006-12-28 2008-07-10 International Institute Of Cancer Immunology, Inc. Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
US20080199485A1 (en) 2007-02-15 2008-08-21 Mannkind Corporation Method for enhancing T cell response
WO2008113970A2 (en) 2007-03-16 2008-09-25 Ucl Business Plc Peptides
EP2155782A2 (en) 2007-03-26 2010-02-24 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
KR101530395B1 (ko) 2007-04-27 2015-06-19 피페넥스 인크. 향상된 수율 및(또는) 품질로 이종 단백질을 발현하는 특정 균주를 동정하기 위해 미생물 숙주를 신속히 스크리닝하는 방법
US8933197B2 (en) 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
US8926961B2 (en) 2007-10-03 2015-01-06 Board Of Trustees Of The University Of Arkansas HPV E6 protein T cell epitopes and uses thereof
CN101418309B (zh) 2007-10-23 2011-05-04 中国农业科学院上海兽医研究所 柔嫩艾美耳球虫蛋白质二硫键异构酶基因的克隆、表达及应用
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
EP2172211B1 (en) 2008-10-01 2014-12-03 Immatics Biotechnologies GmbH Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
EP2184070A1 (en) 2008-11-07 2010-05-12 Hla-G Technologies HLA-G proteins and pharmaceutical uses thereof
MX2011007647A (es) 2009-01-21 2011-09-01 Amgen Inc Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
BR122021021381B1 (pt) 2009-02-03 2023-05-16 Amunix Pharmaceuticals, Inc Método de aprimoramento de uma propriedade de uma proteína biologicamente ativa
ES2515241T3 (es) 2009-06-25 2014-10-29 Commissariat à l'énergie atomique et aux énergies alternatives Polipéptidos multímeros de HLA-G que incluyen al menos dos dominios alfa3 y usos farmacéuticos de los mismos
LT2504364T (lt) 2009-11-24 2017-11-10 Medimmune Limited Tiksliniai surišantys agentai prieš b7-h1
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
WO2012007951A1 (en) 2010-07-15 2012-01-19 Technion Research & Development Foundation Ltd. Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides
CN107880136B (zh) 2010-09-21 2021-11-12 阿尔托生物科学有限公司 多聚体il-15可溶性融合分子与其制造与使用方法
US9428567B2 (en) 2010-12-22 2016-08-30 The Board Of Trustees Of The Leland Stanford Junior University Antagonists of interleukin-2 receptor
LT3075745T (lt) * 2011-02-10 2018-11-26 Roche Glycart Ag Mutavę interleukino-2 polipeptidai
WO2012127464A2 (en) 2011-03-23 2012-09-27 Gavish-Galilee Bio Applications Ltd Constitutively activated t cells for use in adoptive cell therapy
CA2833690A1 (en) 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Novel binder-drug conjugates (adcs) and their use
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CN103649125A (zh) 2011-06-22 2014-03-19 霍夫曼-拉罗奇有限公司 利用包含mhc i类的复合物通过循环中的病毒特异性细胞毒性t细胞清除靶细胞
BR112013033661A2 (pt) 2011-06-30 2017-01-24 Genzyme Corp inibidores de ativação de células t
US9494588B2 (en) 2011-08-30 2016-11-15 Jacobs University Bremen Ggmbh Gene coded for a MHC class I molecule, plasmid, expression system protein, multimer, reagent and kit to analyze a T cell frequency
US8956619B2 (en) 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
ES2808152T3 (es) 2011-11-28 2021-02-25 Merck Patent Gmbh Anticuerpos anti-PD-L1 y usos de los mismos
CN104684577B (zh) 2012-01-13 2018-05-08 纪念斯隆凯特林癌症中心 免疫原性wt-1肽及其使用方法
US20150071987A1 (en) 2012-02-03 2015-03-12 Emory University Immunostimulatory compositions, particles, and uses related thereto
BR112015002091A2 (pt) * 2012-08-02 2017-12-12 Hoffmann La Roche método para a produção de um polipeptídeo, polipeptídeo, uso de um polipeptídeo e composição
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
CA2887486A1 (en) 2012-11-30 2014-06-05 Roche Glycart Ag Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class i comprising multi-function proteins
JP2016500255A (ja) 2012-12-11 2016-01-12 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ ハイスループットなレセプター：リガンド同定の方法
RU2015129640A (ru) * 2012-12-21 2017-01-26 Ф.Хоффманн-Ля Рош Аг Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1
EP3769782A1 (en) 2013-01-15 2021-01-27 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
EP3936521B1 (en) 2013-03-15 2026-02-11 Xencor, Inc. Heterodimeric proteins
HK1220376A1 (zh) 2013-03-15 2017-05-05 Angelica Therapeutics, Inc. 修饰的毒素
EP3461493A1 (en) 2013-03-29 2019-04-03 Sumitomo Dainippon Pharma Co., Ltd. Wt1 antigen peptide conjugate vaccine
ES2954899T3 (es) 2013-05-13 2023-11-27 Int Inst Cancer Immunology Inc Procedimiento para predecir el efecto clínico de una inmunoterapia
GB201311475D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Polypeptides
KR102268688B1 (ko) 2013-07-19 2021-06-24 브이아이비 브이지더블유 표적화된 변형된 tnf 패밀리 구성원
EA035319B1 (ru) * 2013-07-31 2020-05-27 Эмджен Инк. СТАБИЛИЗАЦИЯ Fc-СОДЕРЖАЩИХ ПОЛИПЕПТИДОВ
SG11201605632SA (en) 2014-01-21 2016-08-30 Einstein Coll Med Cellular platform for rapid and comprehensive t-cell immunomonitoring
US20160152725A1 (en) 2014-02-25 2016-06-02 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide
CN106029699B (zh) 2014-02-26 2019-07-19 泰来有限公司 Wt1抗原性多肽和含有该多肽的抗肿瘤剂
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
DK3480213T3 (da) 2014-06-18 2020-02-17 Albert Einstein College Medicine Syntac-polypeptider og anvendelser deraf
KR102130600B1 (ko) 2014-07-03 2020-07-08 베이진 엘티디 Pd-l1 항체와 이를 이용한 치료 및 진단
JP6768633B2 (ja) 2014-07-21 2020-10-14 デリニア， インコーポレイテッド 自己免疫疾患を治療するために調節性ｔ細胞を選択的に活性化する分子
DK3180018T3 (da) 2014-08-12 2019-10-28 Massachusetts Inst Technology Synergistisk tumorbehandling med IL-2 og integrinbindende Fc-fusionsprotein
CA2958578A1 (en) 2014-08-21 2016-02-25 The General Hospital Corporation Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the same
ES2774380T3 (es) * 2014-08-29 2020-07-20 Hoffmann La Roche Politerapia de inmunocitocinas de variante de IL-2 dirigida a tumor y anticuerpos frente a PD-L1 humano
AU2015347015B2 (en) 2014-11-14 2019-02-14 Novartis Ag Antibody drug conjugates
SG11201704155UA (en) 2014-11-26 2017-06-29 Us Health Anti-mutated kras t cell receptors
WO2016141357A1 (en) 2015-03-05 2016-09-09 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof
CA2980292A1 (en) 2015-03-23 2016-09-29 The Johns Hopkins University Hla-restricted epitopes encoded by somatically mutated genes
WO2016164937A2 (en) 2015-04-10 2016-10-13 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
HUE054616T2 (hu) 2015-04-17 2021-09-28 Alpine Immune Sciences Inc Immunmodulátor fehérjék hangolható affinitásokkal
JP6920211B2 (ja) 2015-05-06 2021-08-18 ユーティーアイ リミテッド パートナーシップ 持続療法用のナノ粒子組成物
US20180140691A1 (en) 2015-05-20 2018-05-24 Sumitomo Dainippon Pharma Co., Ltd. Combination use of wt1 antigen peptide and immunomodulator
EA201890285A1 (ru) 2015-07-13 2018-08-31 Сайтомкс Терапьютикс, Инк. Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
US11046745B2 (en) 2015-07-14 2021-06-29 BioNTech SE Peptide mimotopes of the CD3 T-cell co-receptor epsilon chain and uses thereof
AU2016303497A1 (en) 2015-07-31 2018-03-01 Tarveda Therapeutics, Inc. Compositions and methods for immuno-oncology therapies
CN106565836B (zh) 2015-10-10 2020-08-18 中国科学院广州生物医药与健康研究院 高亲和力的可溶性pdl-1分子
EP3377516B1 (en) 2015-11-20 2022-06-15 Memorial Sloan Kettering Cancer Center Composition for treating cancer
EP3400069A4 (en) 2016-01-04 2019-09-25 Cour Pharmaceuticals Development Company Inc. Particles for the Encapsulation of Fusion Proteins with Bundled Epitopes
HK1259079A1 (zh) 2016-01-11 2019-11-22 Rubius Therapeutics, Inc. 与免疫适应症的多模式治疗性细胞体系有关的组合物和方法
EP3408279A1 (en) 2016-01-27 2018-12-05 CSL Behring Lengnau AG Recombinant igg fc multimers
EP3423108A4 (en) 2016-03-02 2019-10-02 Cue Biopharma, Inc. T CELL MODULATING MULTIPLE POLYPEPTIDES AND METHOD OF USE THEREOF
CN109414498A (zh) * 2016-03-03 2019-03-01 Cue生物制药公司 T细胞调节性多聚体多肽及其使用方法
EP3436059B1 (en) 2016-04-01 2022-01-12 Innovative Cellular Therapeutics Holdings, Ltd. Use of chimeric antigen receptor modified cells to treat cancer
BR112018073606A2 (pt) 2016-05-18 2019-02-26 Cue Biopharma, Inc. polipeptídeos multiméricos moduladores de células t e métodos de uso dos mesmos
EP3458095A4 (en) 2016-05-18 2019-11-27 Albert Einstein College of Medicine VARIANT PD-L1 POLYPEPTIDE, T-CELL MODULATING MULTIPLE POLYPEPTIDE AND METHOD OF USE THEREOF
CA3036966A1 (en) 2016-09-16 2018-03-22 Baylor College Of Medicine Platform for activation and expansion of virus-specific t-cells
DK3538559T3 (da) 2016-11-09 2025-07-14 Uti Lp Rekombinante pmhc klasse ii-molekyler
CN110325205B (zh) 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
EP3565535A4 (en) 2017-01-05 2020-12-30 Fred Hutchinson Cancer Research Center SYSTEMS AND METHODS FOR IMPROVING THE EFFECTIVENESS OF A VACCINE
WO2018129474A1 (en) 2017-01-09 2018-07-12 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CN110662556A (zh) 2017-03-09 2020-01-07 哈佛大学的校长及成员们 癌症疫苗
CN111010875B (zh) 2017-03-15 2024-04-05 库尔生物制药有限公司 用于调节免疫应答的方法
CN119409836A (zh) 2017-03-17 2025-02-11 弗雷德哈钦森癌症中心 免疫调节融合蛋白及其用途
WO2019005886A1 (en) 2017-06-26 2019-01-03 The Broad Institute, Inc. CRISPR / CAS-CYTIDINE DEAMINASE COMPOSITIONS, SYSTEMS AND METHODS FOR TARGETED EDITING OF NUCLEIC ACIDS
EP3446702A1 (en) 2017-08-23 2019-02-27 Medizinische Hochschule Hannover Synthetic vaccine
CN111315768A (zh) 2017-09-07 2020-06-19 库尔生物制药有限公司 具有缀合位点的t细胞调节性多聚体多肽及其使用方法
TW201920247A (zh) 2017-09-07 2019-06-01 美商信號生物製藥公司 抗原呈現多肽及其使用方法
TW201925235A (zh) 2017-09-07 2019-07-01 美商信號生物製藥公司 具有化學結合位點之抗原呈現多肽及其使用方法
JP2020533273A (ja) 2017-09-07 2020-11-19 キュー バイオファーマ， インコーポレイテッド 多量体ｔ細胞調節ポリペプチドおよびその使用方法
MA50613A (fr) 2017-10-03 2020-08-12 Editas Medicine Inc Molécules de liaison spécifique à l'hpv
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2019162937A1 (en) 2018-02-20 2019-08-29 Technion Research & Development Foundation Limited Immunotherapeutic composition for the treatment of cancer
EP3865146A4 (en) 2018-10-05 2022-06-29 International Institute of Cancer Immunology, Inc. Prophylactic or therapeutic drug for benign tumor
WO2020132136A1 (en) 2018-12-19 2020-06-25 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
EP3897746A4 (en) 2018-12-19 2022-10-26 Cue Biopharma, Inc. MULTIMERIC T LYMPHOCYTE MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF
WO2020132365A2 (en) 2018-12-19 2020-06-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
WO2020132366A2 (en) 2018-12-19 2020-06-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
WO2020132368A1 (en) 2018-12-19 2020-06-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
WO2020132135A1 (en) 2018-12-19 2020-06-25 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
TWI856047B (zh) 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
EP3935079A4 (en) 2019-03-06 2023-03-22 Cue Biopharma, Inc. T-CELL MODULATING ANTIGEN PRESENT POLYPEPTIDES AND METHODS OF USE THEREOF
JP2022522405A (ja) 2019-03-06 2022-04-19 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
CN113939310A (zh) 2019-03-30 2022-01-14 百欧恩泰美国公司 用于制备t细胞组合物的组合物和方法及其用途
WO2020243315A1 (en) 2019-05-29 2020-12-03 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
CN114786708A (zh) 2019-06-05 2022-07-22 亚设生物治疗公司 用于调节免疫细胞功能的突变体白介素-2多肽与抗原结合分子的融合物
EP3986448A4 (en) 2019-06-19 2023-07-12 Cue Biopharma, Inc. MULTIMERIC T-CELL-MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF
EP4030897A4 (en) 2019-09-20 2023-10-18 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
EP4048689A4 (en) 2019-10-23 2023-11-01 Cue Biopharma, Inc. T-CELL MODULATING CHIMERIC MOLECULES AND METHOD OF USE THEREOF
CN114423497A (zh) 2019-10-23 2022-04-29 库尔生物制药有限公司 修饰的细胞毒性t细胞及其使用方法
CN114901678A (zh) 2019-12-02 2022-08-12 瑞泽恩制药公司 肽-mhc ii蛋白构建体及其用途
KR20220116513A (ko) 2019-12-20 2022-08-23 리제너론 파아마슈티컬스, 인크. 신규 il2 작용제 및 이의 사용 방법
JPWO2021172595A1 (pl) 2020-02-28 2021-09-02
WO2021195411A1 (en) 2020-03-25 2021-09-30 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
GB202005617D0 (en) 2020-04-17 2020-06-03 Adaptimmune Ltd Improved t cell manufacturing process
EP4149534A4 (en) 2020-05-12 2024-09-04 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING T CELLS AND METHODS OF USE THEREOF
CN115867303A (zh) 2020-05-12 2023-03-28 住友制药株式会社 用于治疗癌症的药物组合物
CN113823723A (zh) * 2020-06-18 2021-12-21 光宝光电(常州)有限公司 发光二极管封装结构
IL299834A (en) 2020-07-14 2023-03-01 Cue Biopharma Inc with binding sites and methods for using them T - cellular modulatory polypeptides
WO2022087458A1 (en) 2020-10-23 2022-04-28 Asher Biotherapeutics, Inc. Fusions with cd8 antigen binding molecules for modulating immune cell function
WO2022099156A2 (en) 2020-11-06 2022-05-12 Cue Biopharma, Inc. T-cell modulatory polypeptides with conjugation sites and methods of use thereof
WO2022119958A1 (en) 2020-12-02 2022-06-09 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2022125694A1 (en) 2020-12-09 2022-06-16 Asher Biotherapeutics, Inc. Fusions of interleukin polypeptides with bispecific antigen binding molecules for modulating immune cell function
JP2023553216A (ja) 2020-12-09 2023-12-20 アシャ バイオセラピューティクス，インク． 遺伝子操作細胞療法のための標的化サイトカイン構築物
AU2022238389A1 (en) 2021-03-19 2023-10-05 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
WO2022226058A1 (en) 2021-04-22 2022-10-27 Cue Biopharma, Inc. Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof
WO2023081718A1 (en) 2021-11-04 2023-05-11 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2023097188A1 (en) 2021-11-24 2023-06-01 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2023137156A2 (en) 2022-01-13 2023-07-20 Cue Biopharma, Inc. T cell modulatory polypeptides with conjugation sites and methods of use thereof

Also Published As

Publication number Publication date
US20240076344A1 (en) 2024-03-07
US12145973B2 (en) 2024-11-19
EP4360647A3 (en) 2024-07-24
AU2017379900B2 (en) 2024-12-05
JP2023113888A (ja) 2023-08-16
US20250092110A1 (en) 2025-03-20
IL266696A (en) 2019-07-31
US20220340632A1 (en) 2022-10-27
US11377478B2 (en) 2022-07-05
WO2018119114A1 (en) 2018-06-28
US20210107962A1 (en) 2021-04-15
CN117024560A (zh) 2023-11-10
US11708400B2 (en) 2023-07-25
US11505588B2 (en) 2022-11-22
US20240083964A1 (en) 2024-03-14
US20220356224A1 (en) 2022-11-10
US20240199715A1 (en) 2024-06-20
PT3558339T (pt) 2024-03-15
CN116970060A (zh) 2023-10-31
IL308851B2 (en) 2025-07-01
KR20190111022A (ko) 2019-10-01
JP2023027295A (ja) 2023-03-01
EP3558339B1 (en) 2024-01-24
IL303806B2 (en) 2024-05-01
US10927158B2 (en) 2021-02-23
PH12019501413A1 (en) 2020-03-16
TW202400216A (zh) 2024-01-01
BR112019012964A2 (pt) 2019-10-08
IL308851A (en) 2024-01-01
JP7403703B2 (ja) 2023-12-22
US20200207824A1 (en) 2020-07-02
JP2024037852A (ja) 2024-03-19
IL297617B1 (en) 2023-07-01
US12421287B2 (en) 2025-09-23
US20230220032A1 (en) 2023-07-13
IL266696B (en) 2022-12-01
CN110325205B (zh) 2023-08-15
US20210198337A1 (en) 2021-07-01
JP7250677B2 (ja) 2023-04-03
US12180258B2 (en) 2024-12-31
US20240141006A1 (en) 2024-05-02
JP7295325B2 (ja) 2023-06-20
AU2017379900A1 (en) 2019-06-13
EP4360647A2 (en) 2024-05-01
MY202029A (en) 2024-03-29
US11739133B2 (en) 2023-08-29
DK3558339T5 (da) 2024-09-02
US20260049116A1 (en) 2026-02-19
US20220064247A1 (en) 2022-03-03
JP2020511949A (ja) 2020-04-23
SI3558339T1 (sl) 2024-05-31
US20200199181A1 (en) 2020-06-25
US11370821B2 (en) 2022-06-28
US20220289808A1 (en) 2022-09-15
US12152061B2 (en) 2024-11-26
US11117945B2 (en) 2021-09-14
US11530248B2 (en) 2022-12-20
CA3043630A1 (en) 2018-06-28
US11905320B2 (en) 2024-02-20
IL297617A (en) 2022-12-01
IL303806A (en) 2023-08-01
EP3558339A4 (en) 2020-08-19
TWI869327B (zh) 2025-01-11
IL266696B2 (en) 2023-04-01
US20220033456A1 (en) 2022-02-03
CN116970061A (zh) 2023-10-31
DK3558339T3 (da) 2024-02-26
IL308851B1 (en) 2025-03-01
IL297617B2 (en) 2023-11-01
EP3558339A1 (en) 2019-10-30
US20190352363A1 (en) 2019-11-21
CN117903282A (zh) 2024-04-19
US20220177536A1 (en) 2022-06-09
US11401314B2 (en) 2022-08-02
KR102760578B1 (ko) 2025-02-03
US11987610B2 (en) 2024-05-21
JP7560641B2 (ja) 2024-10-02
TWI852752B (zh) 2024-08-11
MX2023013883A (es) 2023-12-11
US20250243253A1 (en) 2025-07-31
CN116970059A (zh) 2023-10-31
MX2019007611A (es) 2020-07-29
US20230399372A1 (en) 2023-12-14
TW201829451A (zh) 2018-08-16
IL303806B1 (en) 2024-01-01
ES2973548T3 (es) 2024-06-20
US20230257439A1 (en) 2023-08-17
US11851467B2 (en) 2023-12-26
CN110325205A (zh) 2019-10-11

Similar Documents

Publication Publication Date Title
PL3558339T3 (pl) Multimeryczne polipeptydy modulujące limfocyty t i sposoby ich stosowania
IL271025A (en) Multibiotic agents and methods of using the same
IL272085A (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
DK3436048T3 (da) Neoantigener og fremgangsmåder til anvendelse deraf
IL282372A (en) Haploid induction compositions and methods for use therefor
DK3534899T3 (da) Forbindelser og fremgangsmåder til modulering af interleukin-2-inducerbar t-cellekinase
DK3601358T3 (da) Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf
DK3618863T3 (da) Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf
DK3356404T3 (da) Anti-pd1-antistoffer og fremgangsmåder til anvendelse
DK3353210T3 (da) Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse
DK3551660T5 (da) Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
DK3436030T3 (da) Kimæriske receptorer og fremgangsmåder til anvendelse deraf
IL251972B (en) Analyzing and utilizing landscapes
DK3215532T3 (da) Anti-TIM3-antistoffer og fremgangsmåder til anvendelse
DK3259597T3 (da) Pvrig-polypeptider og fremgangsmåder til behandling
DK3230319T3 (da) Anti-PD-1-antistoffer og fremgangsmåder til anvendelse deraf
DK3249777T3 (da) Adapter og fremgangsmåde til opladningskontrol
PL3551664T3 (pl) Przeciwciała i polipeptydy skierowane przeciwko cd127
DK3148579T3 (da) Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
DK3668512T3 (da) Pyruvatkinasemodulatorer og anvendelse deraf
DK3221357T3 (da) Fælles letkæder og fremgangsmåder til anvendelse
DK3653221T3 (da) Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3185868T3 (da) Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme
DK3525583T3 (da) Anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf